SCYNEXIS (SCYX) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	SCYNEXIS INC
Entity Central Index Key	1178253
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,903,832

Unaudited_Condensed_Balance_Sh

Unaudited Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$27,620	$32,243
Accounts receivable	681	1,118
Unbilled services	372	383
Prepaid expenses and other current assets	1,157	992
Total current assets	29,830	34,736
Property and equipment, net of accumulated depreciation	4,674	4,835
Other assets	96	101
Deferred offering costs	257	0
Total assets	34,857	39,672
Liabilities and stockholders’ equity
Accounts payable	1,372	855
Accrued expenses	3,280	2,497
Deferred revenue, current portion	480	449
Total current liabilities	5,132	3,801
Deferred revenue, net of current portion	1,050	1,146
Deferred rent	1,237	1,294
Total liabilities	7,419	6,241
Commitments and contingencies (Note 5)
Stockholders' deficit:
Common stock	8	8
Additional paid-in capital	151,325	150,934
Accumulated deficit	-123,895	-117,511
Total stockholders’ equity	27,438	33,431
Total liabilities and stockholders’ equity	$34,857	$39,672

Unaudited_Condensed_Balance_Sh1

Unaudited Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	8,527,210	8,512,103
Common stock, shares outstanding	8,527,210	8,512,103

Unaudited_Condensed_Statements

Unaudited Condensed Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue — related party	$987	$1,822
Revenue	2,310	2,883
Total revenue	3,297	4,705
Cost of revenue	3,231	3,960
Gross profit	66	745
Operating expenses:
Research and development	4,218	1,320
Selling, general and administrative	2,233	1,206
Total operating expenses	6,451	2,526
Loss from operations	-6,385	-1,781
Other (income) expense:
Amortization of deferred financing costs and debt discount	0	536
Interest (income) expense	-1	44
Derivative fair value adjustment	0	-2,783
Other expense	0	10
Total other (income) expense:	-1	-2,193
Net (loss) income	-6,384	412
Deemed dividend for beneficial conversion feature on Series D-2 preferred stock	0	-909
Deemed dividend for antidilution adjustments to convertible preferred stock	0	-214
Accretion of convertible preferred stock	0	-510
Net loss attributable to common stockholders - basic	-6,384	-1,221
Derivative fair value adjustment	0	-2,783
Net loss attributable to common stock - diluted	($6,384)	($4,004)
Net loss per share attributable to common stockholders:
Basic (USD per share)	($0.75)	($3.65)
Diluted (USD per share)	($0.75)	($6.57)
Weighted average common shares outstanding:
Basic (shares)	8,516,467	334,086
Diluted (shares)	8,516,467	609,074

Unaudited_Condensed_Statements1

Unaudited Condensed Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net (loss) income	($6,384)	$412
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	323	308
Stock-based compensation expense	296	110
Amortization of deferred financing costs and debt discount	0	536
Change in fair value of derivative liability	0	-2,783
Changes in deferred rent	-57	-15
Changes in operating assets and liabilities:
Accounts receivable and unbilled services	448	-275
Prepaid expenses, other assets, and deferred costs	-160	186
Accounts payable and accrued expenses	1,052	635
Deferred revenue	-65	1,047
Net cash (used in) provided by operating activities	-4,547	161
Cash flows from financing activities:
Purchases of property and equipment	-171	-74
Net cash used in investing activities	-171	-74
Cash flows from financing activities:
Proceeds from sale of preferred stock	0	544
Payments of deferred offering costs and underwriting discounts and commissions	0	-1,388
Proceeds from employee stock purchase plan issuance	95	0
Proceeds from exercise of stock options	0	5
Net cash provided by (used in) financing activities	95	-839
Net decrease in cash and cash equivalents	-4,623	-752
Cash and cash equivalents, beginning of period	32,243	1,402
Cash and cash equivalents, end of period	27,620	650
Supplemental cash flow information:
Cash paid for interest	0	45
Noncash financing and investing activities:
Beneficial conversion feature on sale of Series D-2 preferred stock	0	909
Beneficial conversion feature for antidilution adjustment	0	214
Adjustment of preferred stock to redemption value	0	-510
Issuance of warrants with preferred stock	0	544
Deferred offering costs included in accounts payable and accrued expenses	257	1,715
Equipment purchases in accounts payable and accrued expenses	$25	$204

Description_of_Business_and_Ba

Description of Business and Basis of Preparation	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Description of Business and Basis of Preparation	Description of Business and Basis of Preparation
	Organization
	SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a pharmaceutical company, headquartered in Durham, North Carolina, committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. The Company also offers its services in drug discovery and development, primarily in the form of integrated research teams consisting of medicinal, computational, analytical, and process scientists working on a collaborative basis with its customers on research projects.
	Unaudited Interim Financial Information
	The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results for the full year or the results for any future periods. These financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC") on March 30, 2015.
	Use of Estimates
	The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the accounts receivable allowance; the valuation of the related-party deemed contribution; the fair value of the Company’s common stock used to measure stock-based compensation for options granted to employees and nonemployees and to determine the fair value of common stock warrants; the fair value of convertible preferred stock; the fair value of the Company’s derivative liability; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimated useful lives of property and equipment.
	Reverse Stock-split
	On March 17, 2014, the Company amended its amended and restated certificate of incorporation to implement a 1-for-4 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties.
	On April 25, 2014, the Company amended its amended and restated certificate of incorporation to implement an additional 1-for-5.1 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company further adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties.
	All disclosures of common shares and per common share data in the accompanying interim financial statements and related notes reflect these two reverse stock splits for all periods presented.
	Initial Public Offering
	On May 7, 2014, the Company completed an initial public offering (“IPO”) of its common stock. The Company sold an aggregate of 6,200,000 shares of common stock at a public offering price of $10.00 per share. Net proceeds were $54,583, after deducting underwriting discounts and commissions of $3,290 and offering expenses of $4,127. Upon the completion of the IPO, all outstanding shares of the Company’s convertible preferred stock were automatically converted into 1,691,884 shares of common stock and certain outstanding warrants were exercised for an additional 275,687 shares of common stock. In connection with the consummation of the IPO, the Company repaid outstanding debt with a principal balance of $15,000, plus all accrued interest, to the holder of such debt, which was outstanding pursuant to a credit agreement referred to herein as the 2013 Credit Agreement. The significant increase in the shares outstanding beginning in May 2014 has impacted the comparability of the Company's net earnings (loss) per share calculations between interim 2015 and 2014 periods.
	April 2015 Follow-on Public Offering
	On April 28, 2015, the Company completed a follow-on public offering (the "April 2015 offering") of its common stock. The Company sold an aggregate of 5,376,622 shares of common stock at a public offering price of $7.70 per share. Net proceeds were approximately $37,754, after deducting underwriting discounts and commissions and estimated offering expenses of approximately $3,646. The Company incurred $257 of the total estimated offering expenses as of March 31, 2015, which have been capitalized as deferred offering costs in the accompanying balance sheets. The significant increase in the shares outstanding beginning in April 2015 is expected to impact the year-over-year comparability of the Company’s net (loss) earnings per share calculations for the next twelve months.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Deferred Offering Costs
	Deferred offering costs are expenses directly related to the IPO or the April 2015 offering. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 offering will be offset against the proceeds from the April 2015 offering and will be reclassified to additional paid-in capital upon completion of the April 2015 offering.
	Revenue Recognition and Deferred Revenue
	The Company derives the majority of its revenue from providing contract research and development services under fee for service arrangements. The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations.
	Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed.
	When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements. If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered.
	Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date.
	The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement.
	Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets.
	The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods. The Company received non-refundable upfront payments of $313, $1,500 and $500 in August 2012, August 2013 and January 2014, respectively, which are recognized over periods of six months, 70 months and 48 months, respectively. The Company recognized revenue from these upfront payments of $96 and $93 for the three months ended March 31, 2015 and 2014, respectively.
	Collaboration Arrangements
	The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement.
	The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $420 and $226 as of March 31, 2015 and December 31, 2014, respectively, which are presented as other current assets in the accompanying balance sheets.
	Research and Development
	Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance.
	The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel.
	Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the quarter ended March 31, 2015. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2015 and 2014, is presented as follows:
		Three Months Ended March 31,
		2015		2014
	Research and development expense, gross	$	4,412	$	1,320
	Less: Reimbursement of research and development expense	194		—
	Research and development expense, net of reimbursements	$	4,218	$	1,320
	Effect of Recent Accounting Pronouncements
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and will apply, as applicable, to future dispositions or classifications as held for sale.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The FASB has proposed a delay in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Property and equipment consists of the following:
		March 31,		December 31,
		2015		2014
	Equipment	$	8,698	$	8,552
	Furniture and fixtures	375		375
	Leasehold improvements	13,209		13,193
	Total property and equipment	22,282		22,120
	Less accumulated depreciation	17,608		17,285
	Property and equipment, net	$	4,674	$	4,835
	Depreciation expense was $323 and $308 for the three months ended March 31, 2015 and 2014, respectively.

Debt_Obligations

Debt Obligations	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Obligations	Debt Obligations
	Credit Facility Agreement
	In April 2010, the Company entered into a $15,000 credit facility agreement with HSBC Bank (the “2010 Credit Agreement”). The agreement comprised a $5,000 term loan and a $10,000 revolving credit facility. Borrowings under the 2010 Credit Agreement carried interest at a rate of London InterBank Offered Rate plus 0.95% per annum. The 2010 Credit Agreement required interest-only payments through March 2013 and was guaranteed by a related party that has an investment in the Company. All outstanding borrowings under the agreement were originally due on March 11, 2013. The 2010 Credit Agreement contained no financial covenants.
	On March 8, 2013, the Company entered into an agreement to amend the 2010 Credit Agreement with HSBC Bank (the “2013 Credit Agreement”). The 2013 Credit Agreement required interest-only payments through December 2014 when all outstanding borrowings were due. Other significant terms of the 2010 Credit Agreement remained the same, which included the guarantee made by a related party that has an investment in the Company. The 2013 Credit Agreement represented a new loan, and the Company determined the value of the extended guarantee under the 2013 Credit Agreement to be $3,930, which was amortized over the term of the 2013 Credit Agreement.
	Pursuant to an addendum dated April 29, 2014, upon completion of the IPO on May 7, 2014, the entire outstanding balance of the 2013 Credit Agreement, amounting to $15,000 plus accrued interest, was paid in full using the proceeds from the IPO. The payment on May 7, 2014, released the related party guarantor from all obligations, under and in relation to the 2013 Credit Agreement. The Company recorded a loss on the extinguishment of debt of $1,389 in the three month period ended June 30, 2014, as the remaining deferred financing costs associated with the 2013 Credit Agreement were written off. The Company had no outstanding debt as of March 31, 2015 and as of December 31, 2014.
	Amortization of deferred financing costs associated with the 2010 Credit Agreement and 2013 Credit Agreement was $0 and $536 for the three months ended March 31, 2015 and 2014, respectively.
	Note and Warrant Purchase Agreements
	In December 2011, the Company executed a Note and Warrant Purchase Agreement (the “December 2011 Note and Warrant Agreement”) to issue convertible notes in an aggregate amount not to exceed $15,000. In 2011 and 2012, under the December 2011 Note and Warrant Agreement, the Company issued convertible notes (the “2011-2012 Notes”) with a total principal amount of $11,444 to related parties that held investments in the Company. The 2011-2012 Notes included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The 2011-2012 Notes were convertible into shares of the Company’s stock under various methods as stipulated in the agreement.
	In June 2013, the Company executed another Note and Warrant Purchase Agreement (the “June 2013 Note and Warrant Agreement”) with certain existing lenders. Under the June 2013 Note and Warrant Agreement, the lenders agreed to loan to the Company up to $1,500 in exchange for convertible notes (the “June 2013 Notes”). The Company issued June 2013 Notes for an aggregate amount of $899. In addition, the Company agreed to issue warrants to purchase shares of the Company’s common stock upon the request of a majority of the noteholders. The June 2013 Notes were convertible into shares of the Company’s stock using methods described in the agreement. In addition, the June 2013 Notes included conversion of the entire outstanding principal and interest balance into equity securities upon the closing of any equity financing at the option of the noteholders.
	On December 11, 2013, the noteholders elected to convert the June 2013 Notes into shares of Series D-2 convertible preferred stock. Also on December 11, 2013, the noteholders elected to convert the 2011-2012 Notes into shares of Series D-1 and Series D-2 convertible preferred stock. There was no outstanding principal or accrued interest associated with the 2011-2012 Notes and June 2013 Notes as of December 31, 2014 or as of March 31, 2015.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Leases
	The Company leases its facilities and certain office equipment under long-term non-cancelable operating leases. The Company’s lease for its primary North Carolina facility expires in 2019. The lease agreement includes a renewal option to extend the lease through March 31, 2024.
	Rent expense was approximately $218 and $231 for the three months ended March 31, 2015 and 2014, respectively. Future minimum lease payments for all operating leases as of March 31, 2015 are as follows:
	2015	$	826
	2016	1,122
	2017	1,140
	2018	1,161
	2019	291
	Thereafter	—
	Total	$	4,540
	License Arrangement with Potential Future Expenditures
	As of March 31, 2015, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, that involves potential future expenditures. Under the license arrangement, the Company exclusively licensed from Merck its rights to SCY-078 in the field of human health. SCY-078 is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19,000 upon occurrence of specific events, including initiation of a phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalties are mid- to high-single digits.
	In December 2014, the Company and Merck entered into an amendment to the license agreement that defers the remittance of a milestone payment due to Merck, such that no amount will be due upon initiation of the first phase 2 clinical trial of a product containing the SCY-078 compound (the "Deferred Milestone"). The amendment also increases, in an amount equal to the Deferred Milestone, the milestone payment that will be due upon initiation of the first Phase 3 clinical trial of a product containing the SCY-078 compound. Except as described above, all other terms and provisions of the license agreement remain in full force and effect.
	The Company has two additional licensing agreements for other compounds that could require it to make payments of up to $2,300 upon achievement of certain milestones by the Company.
	Clinical Development Arrangement
	In June 2014, the Company entered into an agreement with a third-party clinical research organization to conduct a Phase 2 clinical trial for SCY-078. The scope of the services under the agreement can be modified at any time, and the agreement can be terminated by either party 30 days after receipt of written notice.
	Other Arrangements
	The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its contract research and development services business (Note 13). Pursuant to the terms of the agreement, in the event that the Company is able to complete a divestiture of its contract research and development services business to a third-party, the Company is obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration.
	In May 2015, the Company's board of directors approved, and the Company communicated, the material terms of a compensatory plan (the "compensatory plan") for the non-executive employees of its contract research and development services business, or the service business. The compensatory plan is designed to promote the retention of services of such non-executive employees in connection with the potential sale of the service business. The Company's obligations under the compensatory plan are contingent upon the successful closing of the potential sale of the service business. The material terms of the compensatory plan are described in Note 14, Subsequent Events, below.

Convertible_Preferred_Stock

Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock
	The Company issued multiple series of convertible preferred stock between 2000 and January 2014. In March 2014, the Company amended its amended and restated certificate of incorporation to require the automatic conversion of all series of convertible preferred stock into common stock upon the completion of a public offering of common stock with gross proceeds of at least $20,000. In May 2014, upon completion of the IPO, all outstanding shares of convertible preferred stock were converted into an aggregate of 1,691,884 shares of common stock at their respective conversion prices.
	Warrants Associated with Preferred Stock Issuances
	In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Convertible Preferred Stock, which converted into the right to purchase 14,033 shares of our common stock in connection with our IPO, however, we refer to these warrants as our Series C-1 Preferred warrants. The Series C-1 Preferred warrants were issued conjunction with a loan financing agreement with an original exercise price of $3.25 per share of Series C-1 Preferred, which converted into an exercise price of $45.61 per share of common stock in connection with our IPO. These warrants remain outstanding as of March 31, 2015 and will expire on July 14, 2016. The fair value at the date of grant for these instruments was $459, which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. The Company recorded other income associated with the fair value adjustment for these warrants of $0 and $37 for three months ended March 31, 2015 and March 31, 2014, respectively.
	On December 11, 2013, the Company entered into an agreement to sell 1,785,712 shares of Series D-2 Convertible Preferred Stock ("Series D-2 Preferred") at $1.40 per share for an aggregate price of $2,500 (the “Series D-2 Purchase Agreement”), less issuance costs of $95. The Series D-2 Purchase Agreement included warrants to purchase 87,532 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $4,214, which was recorded as a discount to the Series D-2 Preferred. The fair value of the warrants was $1,714 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 7, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO.
	On January 31, 2014, the Company sold 388,641 shares of Series D-2 Preferred to related parties under the Series D-2 Purchase Agreement at $1.40 per share, for an aggregate price of $544. The sale also included warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $906. The fair value of the warrants was $362 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 7, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO.

Common_Stock

Common Stock	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Common Stock	Common Stock
	Authorized, Issued, and Outstanding Common Shares
	The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares at March 31, 2015, and December 31, 2014; 8,527,210 and 8,512,103 shares were issued and outstanding at March 31, 2015, and December 31, 2014, respectively. The following table summarizes common stock share activity for the three months ended March 31, 2015:
		Shares of
		Common Stock
	Balance, December 31, 2014	8,512,103
	Common stock issued through employee stock purchase plan	15,107
	Balance, March 31, 2015	8,527,210
	Shares Reserved for Future Issuance
	The Company had reserved shares of common stock for future issuance as follows:
		As of	As of
		March 31,	December 31,
		2015	2014
	Outstanding stock options	575,416	615,322
	Outstanding Series C-1 Preferred warrants	14,033	14,033
	For possible future issuance under 2014 Equity Incentive Plan (Note 8)	561,000	180,610
	For possible future issuance under Employee Stock Purchase Plan (Note 8)	52,050	37,746
	For possible future issuance under 2015 Inducement Plan (Note 8)	450,000	—
	Total common shares reserved for future issuance	1,652,499	847,711
	Common Stock Warrants
	The Company had outstanding common stock warrants issued in connection with the Note and Warrant Purchase Agreements (Note 4) and in connection with certain convertible preferred stock agreements (Note 6).
	The December 2011 Note and Warrant Purchase Agreement included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The warrants could be exercised for shares of common stock, in accordance with their terms. The number of shares of common stock that could be purchased by exercising the warrants would vary based on the event that occurred and would be calculated in accordance with the December 2011 Note and Warrant Purchase Agreements (Note 4).
	On December 11, 2013, holders of the June 2013 Notes exercised their rights under the June 2013 Note and Warrant Agreement to receive warrants to purchase shares of the Company’s common stock. As a result of this exercise, the Company issued warrants to purchase 88,987 shares of the Company’s common stock to the holders of the June 2013 Notes at an exercise price of $0.20 per share. These warrants were exercisable until June 28, 2018, and were exercised in connection with the IPO.
	On December 11, 2013, in connection with the Series D-2 Convertible Preferred Stock offering, the Company issued warrants to purchase 87,532 shares of the Company’s common stock at an exercise price of $0.20 per share. These warrants were exercisable until December 11, 2018, and were exercised in connection with the IPO. In addition, as a result of the conversion of the principal and interest outstanding on the 2011-2012 Notes into Series D-1 Preferred and Series D-2 Preferred (Note 4), in accordance with the amended terms of the agreement, the number of common shares underlying the warrants issued in connection with the 2011-2012 Notes was increased by 54,120 to a total of 80,120.
	In connection with the consummation of the IPO in May 2014, the outstanding common stock warrants were exercised at an exercise price of $0.20 per share and the holders received 275,687 shares of common stock.
	All previously described warrants met the definition of a derivative financial instrument and were accounted for as derivatives. The warrants were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO. The combined fair value of the common stock warrant derivative liabilities, including warrants issued with the sale of Series D-2 Preferred, was $12,200 as of December 31, 2013, and then decreased to $9,998 as of March 31, 2014. The combined fair value of the common stock warrant derivative liabilities continued to decrease in the second quarter of 2014 to $2,701 as of May 2, 2014, and this amount was settled to additional paid in capital on that date as the warrants were exercised in conjunction with the Company's IPO. The fair value adjustment of the long-term derivative liability was recorded as other income in the amounts of $0 and $3,108 for the three months ended March 31, 2015 and March 31, 2014, respectively.

Stockbased_Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation
	2009 Stock Option Plan
	The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant.
	2014 Equity Incentive Plan
	In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards.
	Under the 2014 Plan, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 257,352 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year. The Board of Directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur.
	On June 18, 2014, the Company’s Board of Directors and Compensation Committee approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of the Company’s common stock that may be issued under the 2014 Plan by an additional 351,653 shares. All other material terms of the 2014 Plan remained unchanged. The Company’s stockholders approved the 2014 Plan amendment on September 11, 2014.
	Pursuant to the terms of the 2014 Plan, on January 1, 2015, the Company automatically added 340,484 shares to the total number of shares of common stock available for future issuance under the 2014 Plan. In connection with the resignation of the Company's Chief Medical Officer, Dr. Carole Sable, effective as of February 20, 2015, the Company returned 57,452 shares to the total number shares of common stock available for future issuance under the 2014 Plan. The returned shares represent Dr. Sable's unvested shares as of the effective date of her resignation.
	On February 25, 2015, the Company's Board of Directors approved an amendment of the 2014 Plan, subject to stockholder approval at the Company's 2015 annual meeting of stockholders to be held on June 4, 2015, to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2014 Plan by an additional 510,726 shares. All other material terms of the 2014 Plan otherwise remain unchanged.
	As of March 31, 2015, there were 561,000 shares of common stock available for future issuance under the 2014 Plan. See Note 14 for certain events occurring after March 31, 2015, that affected the number of shares of common stock available for future issuance under the 2014 Plan.
	2015 Inducement Plan
	On March 26, 2015, the Company's Board of Directors adopted the 2015 Inducement Plan, or the 2015 Plan. The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635(c)(4). The 2015 Plan has a share reserve covering 450,000 shares of common stock. No awards had been granted under the 2015 Plan as of March 31, 2015.
	2014 Employee Stock Purchase Plan
	In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014. The purpose of the ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code.
	In the quarterly period ended March 31, 2015, the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares pursuant to the terms of the ESPP and the Company issued 15,107 shares of common stock under the ESPP. As of March 31, 2015, there were 52,050 shares of common stock available for future issuance under the ESPP.
	Compensation Cost
	The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, and the ESPP was $296 and $110 for the three months ended March 31, 2015 and 2014, respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was $0 for the three months ended March 31, 2015 and 2014. Cash received from options exercised was $0 and $5 for the three months ended March 31, 2015 and 2014.
	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations:
		Three Months Ended March 31,
		2015		2014
	Cost of revenue	$	33	$	13
	Research and development	52		62
	Selling, general and administrative	211		35
		$	296	$	110

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The Company did not record a federal or state income tax benefit for the three months ended March 31, 2015 and 2014, due to its conclusion that a full valuation allowance is required against the Company’s deferred tax assets.

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share
	The Company uses the two-class method to compute net loss per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the board of directors, that were made to common stockholders, and as a result were considered participating securities.
	Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income or net loss per share during the period.
	The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders:
		Three Months Ended
		March 31,
		2015				2014
	Net (loss) income	$	(6,384	)		$	412
	Deemed dividend for beneficial conversion feature on Series D-2 Preferred	—				(909		)
	Deemed dividend for antidilution adjustments to convertible preferred stock	—				(214		)
	Accretion of convertible preferred stock	—				(510		)
	Net loss attributable to common stock - basic	$	(6,384	)		$	(1,221	)
	Derivative fair value adjustment	—				(2,783		)
	Net loss attributable to common stock - diluted	$	(6,384	)		$	(4,004	)
	Weighted-average common shares outstanding - basic	8,516,467				334,086
	Incremental shares from assumed exercise of common stock warrants	—				274,988
	Weighted-average of outstanding common stock - diluted	8,516,467				609,074
	Net loss per share
	Basic	$	(0.75	)		$	(3.65	)
	Diluted	$	(0.75	)		$	(6.57	)
	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive.
		Three Months Ended
		March 31,
		2015			2014
	Convertible preferred stock:
	Series A Preferred	—			6,149
	Series B Preferred	—			131,685
	Series C Preferred	—			783,515
	Series C-2 Preferred	—			173,213
	Series D-1 Preferred	—			296,773
	Series D-2 Preferred	—			300,549
	Series C-1 Preferred warrants	14,033			14,033
	Stock options	575,416			184,240
	ESPP	40,334			—

RelatedParty_Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions
	The Company had transactions with related parties as follows:
		Three Months Ended March 31,
		2015		2014
	Revenue	$	987	$	1,822
	Sanofi owns 100% of a subsidiary that is a customer of the Company. Both Sanofi and the subsidiary have an investment in the Company. The Company’s related-party revenue with the subsidiary composed 30% and 39% of total revenue for the three months ended March 31, 2015 and 2014, respectively.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled services, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made.
	As of March 31, 2015, and December 31, 2014, there were no assets or liabilities measured at fair value on a recurring basis.
	The Company’s derivative liabilities were the only balance sheet amounts that were measured at fair value on a recurring basis. The fair value of these warrant derivatives was based on a valuation of the Company’s common stock. In order to determine the fair value of the Company’s common stock, the Company used a probability-weighted expected return method, or PWERM. Significant inputs for the PWERM included an estimate of the Company’s equity value, a weighted average cost of capital and an estimated probability and timing for each valuation scenario.
	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:
		Three months ended
		31-Mar-14
	Balance at beginning of period	$	12,237
	Issuance of warrants	544
	Excess of fair value of warrants over proceeds	362
	Adjustment to fair value	(3,145		)
	Balance at end of period	$	9,998
	The fair value of the common stock warrant derivative liabilities decreased from the March 31, 2014 balance presented in the table above during the second quarter of 2014, to $2,701 as of May 2, 2014. The May 2, 2014 balance was then settled to additional paid in capital on that date as the common stock warrants were exercised in conjunction with the IPO.

Assessment_of_Strategic_Altern

Assessment of Strategic Alternatives	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Assessment of Strategic Alternatives	Assessment of Strategic Alternatives
	As part of the Company's strategic objective to focus its resources on the development of SCY-078, the Company's board of directors has directed the Company's management to explore the divestiture of the Company's contract research and development services business. The Company has engaged a third-party firm to assist in the evaluation of several divestiture options (a third-party sale, spin-off, management buy-out or shut-down process). The Company did not meet the relevant criteria for reporting the service business as held for sale as of March 31, 2015, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment.
	In May 2015, the Company's board of directors completed their evaluation of the various divestiture options and directed management to pursue a plan to sell the service business. The Company will continue to evaluate the criteria for reporting the service business as held for sale during 2015, as the Company progresses with respect to a potential sale.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events
	April 2015 Stock Option Grants
	On April 1, 2015, the Company granted options to purchase 425,967 shares of common stock to officers and other key employees, including an award to Dr. Marco Taglietti, the Company's new Chief Executive Officer, to purchase 330,000 shares of the Company's common stock. All options granted on April 1, 2015, shall have a 10-year term. For Dr. Taglietti's grant, one-fourth of the shares subject to the option shall vest on the one-year anniversary of the date of grant with the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Dr. Taglietti continues to provide service to the Company. For all other April 1, 2015 officer and key employee grants, the shares subject to the options shall vest in equal monthly installments for forty-eight months as measured from the date of grant.
	April 2015 Follow-on Public Offering
	On April 28, 2015, the Company completed a follow-on public offering of its common stock. The Company sold an aggregate of 5,376,622 shares of common stock at a public offering price of $7.70 per share. Net proceeds were approximately $37,754, after deducting underwriting discounts and commissions and estimated offering expenses of approximately $3,646.
	Compensatory Plan with Service Business Employees
	In connection with the Company's planned sale of its service business (Note 13), the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting the service business. The Company's board of directors adopted, and the Company communicated, the material terms of the plan in May 2015 to all non-executive employees of the service business. The Company's obligations under the compensatory plan are contingent upon the successful closing of the potential sale of the service business. The compensatory plan terms provide for certain cash compensation payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below.
	Certain non-executive service business employees will receive a cash incentive payment upon the closing of the potential sale transaction. All non-executive employees of the service business will be eligible to receive a cash retention compensation payment from the Company on the earlier of (i) the six month anniversary of the closing of the potential sale transaction, provided that they remain employed by the successor of the service business as of such date, or (ii) the date of termination of such employee by the successor of the service business without good cause. Maximum cash compensation payments could total approximately $1,300 under the compensatory plan, if all service business employees remain eligible pursuant to the plan's terms.
	In addition, the stock options held by each non-executive employee of the service business will be modified immediately prior to the closing of the potential sale transaction to provide: (i) accelerated vesting of all unvested stock options as of the closing of the potential sale transaction and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of May 1, 2015, the non-executive employees of the service business held outstanding options to purchase 55,964 shares of the Company's common stock at a weighted average exercise price of $9.62, including unvested options to purchase 33,274 shares at a weighted average exercise price of $9.62.
	Further, in the event a non-executive employee of the service business is not offered a comparable position by the potential purchaser, the Company intends to provide severance payments to such employees, which are not currently estimable.
	Compensatory Arrangement with Executive Officer
	On May 12, 2015, Charles F. Osborne, Jr., notified the Company that he will be resigning from the Company, including in his capacity as Chief Financial Officer, effective June 30, 2015. The Company's compensation committee of the board of directors approved a compensatory arrangement for Mr. Osborne that provides for certain payments and benefits, including (i) a cash payment of approximately $138,000 upon the effective date of his resignation; (ii) cash severance payments totaling approximately $179,000, which is equal to seven months of Mr. Osborne's current base salary, paid over seven months commencing with the first payroll period following the resignation date; (iii) payment of the COBRA premiums for continued medical, dental, and vision group health coverage for a period up to seven months after the resignation date; and (iv) the vesting and exercisability of all outstanding options to purchase the Company's common stock held by Mr. Osborne will be accelerated in full on the effective date of resignation and the post-employment option exercise period will be extended from 90-days to 36 months. As of June 30, 2015, Mr. Osborne will hold outstanding options to purchase an aggregate of 74,490 shares of the Company's common stock at a weighted average exercise price of $9.53, including unvested options to purchase 50,814 shares at a weighted average exercise price of $9.49.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Deferred Offering Costs	Deferred Offering Costs
	Deferred offering costs are expenses directly related to the IPO or the April 2015 offering. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 offering will be offset against the proceeds from the April 2015 offering and will be reclassified to additional paid-in capital upon completion of the April 2015 offering.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue
	The Company derives the majority of its revenue from providing contract research and development services under fee for service arrangements. The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations.
	Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed.
	When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements. If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered.
	Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date.
	The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement.
	Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets.
	The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods. The Company received non-refundable upfront payments of $313, $1,500 and $500 in August 2012, August 2013 and January 2014, respectively, which are recognized over periods of six months, 70 months and 48 months, respectively. The Company recognized revenue from these upfront payments of $96 and $93 for the three months ended March 31, 2015 and 2014, respectively.
Collaboration Arrangements	Collaboration Arrangements
	The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement.
	The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured.
Research and Development	Research and Development
	Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance.
	The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel.
	Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations.
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and will apply, as applicable, to future dispositions or classifications as held for sale.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The FASB has proposed a delay in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Research and development expenses and reimbursements due	Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the quarter ended March 31, 2015. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2015 and 2014, is presented as follows:
		Three Months Ended March 31,
		2015		2014
	Research and development expense, gross	$	4,412	$	1,320
	Less: Reimbursement of research and development expense	194		—
	Research and development expense, net of reimbursements	$	4,218	$	1,320

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consists of the following:
		March 31,		December 31,
		2015		2014
	Equipment	$	8,698	$	8,552
	Furniture and fixtures	375		375
	Leasehold improvements	13,209		13,193
	Total property and equipment	22,282		22,120
	Less accumulated depreciation	17,608		17,285
	Property and equipment, net	$	4,674	$	4,835

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments for all operating leases as of March 31, 2015 are as follows:
	2015	$	826
	2016	1,122
	2017	1,140
	2018	1,161
	2019	291
	Thereafter	—
	Total	$	4,540

Common_Stock_Tables

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Common Stock Shares Activity	The following table summarizes common stock share activity for the three months ended March 31, 2015:
		Shares of
		Common Stock
	Balance, December 31, 2014	8,512,103
	Common stock issued through employee stock purchase plan	15,107
	Balance, March 31, 2015	8,527,210
Schedule of Reserved Shares of Common Stock for Future Issuance	The Company had reserved shares of common stock for future issuance as follows:
		As of	As of
		March 31,	December 31,
		2015	2014
	Outstanding stock options	575,416	615,322
	Outstanding Series C-1 Preferred warrants	14,033	14,033
	For possible future issuance under 2014 Equity Incentive Plan (Note 8)	561,000	180,610
	For possible future issuance under Employee Stock Purchase Plan (Note 8)	52,050	37,746
	For possible future issuance under 2015 Inducement Plan (Note 8)	450,000	—
	Total common shares reserved for future issuance	1,652,499	847,711

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations:
		Three Months Ended March 31,
		2015		2014
	Cost of revenue	$	33	$	13
	Research and development	52		62
	Selling, general and administrative	211		35
		$	296	$	110

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share	The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders:
		Three Months Ended
		March 31,
		2015				2014
	Net (loss) income	$	(6,384	)		$	412
	Deemed dividend for beneficial conversion feature on Series D-2 Preferred	—				(909		)
	Deemed dividend for antidilution adjustments to convertible preferred stock	—				(214		)
	Accretion of convertible preferred stock	—				(510		)
	Net loss attributable to common stock - basic	$	(6,384	)		$	(1,221	)
	Derivative fair value adjustment	—				(2,783		)
	Net loss attributable to common stock - diluted	$	(6,384	)		$	(4,004	)
	Weighted-average common shares outstanding - basic	8,516,467				334,086
	Incremental shares from assumed exercise of common stock warrants	—				274,988
	Weighted-average of outstanding common stock - diluted	8,516,467				609,074
	Net loss per share
	Basic	$	(0.75	)		$	(3.65	)
	Diluted	$	(0.75	)		$	(6.57	)
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive.
		Three Months Ended
		March 31,
		2015			2014
	Convertible preferred stock:
	Series A Preferred	—			6,149
	Series B Preferred	—			131,685
	Series C Preferred	—			783,515
	Series C-2 Preferred	—			173,213
	Series D-1 Preferred	—			296,773
	Series D-2 Preferred	—			300,549
	Series C-1 Preferred warrants	14,033			14,033
	Stock options	575,416			184,240
	ESPP	40,334			—

RelatedParty_Transactions_Tabl

Related-Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Summary of Transactions with Related Parties	The Company had transactions with related parties as follows:
		Three Months Ended March 31,
		2015		2014
	Revenue	$	987	$	1,822

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:
		Three months ended
		31-Mar-14
	Balance at beginning of period	$	12,237
	Issuance of warrants	544
	Excess of fair value of warrants over proceeds	362
	Adjustment to fair value	(3,145		)
	Balance at end of period	$	9,998

Description_of_Business_and_Ba1

Description of Business and Basis of Preparation - Additional Information (Detail) (USD $)	0 Months Ended				3 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	31-May-14	7-May-14	Apr. 25, 2014	Mar. 17, 2014	Mar. 31, 2015	Apr. 28, 2015	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Formation date					4-Nov-99
Reverse stock split ratio, description					1-for-4 reverse stock split
Reverse stock split ratio			0.196	0.25
Number of shares of common stock sold		6,200,000
Public offering price per share		$10
Net proceeds from initial public offering (IPO)		$54,583
Underwriting discounts and commissions		3,290
Offering expenses		4,127
Number of outstanding shares of convertible preferred stock converted into common stock		1,691,884
Outstanding warrants exercised	275,687	275,687
Deferred offering costs					257		0
Additional Reverse Stock Split [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Reverse stock split ratio, description					1-for-5.1 reverse stock split
2013 Credit Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Repayment of debt		15,000
Subsequent Event [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of shares of common stock sold						5,376,622
Public offering price per share						$7.70
Proceeds from issuance of common shares						37,754
Underwriting discounts and commissions						$3,646

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended			3 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Accounting Policies [Abstract]
Royalty payments received				$0
Upfront payment received	500	1,500	313
Deferred revenue recognition period	48 months	70 months	6 months
Revenue recognized from upfront payments				96	93
Receivables due from R-Pharm				$420		$226

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Research and Development Expenses (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Less: Reimbursement of research and development expense	$4,412	$1,320
Less: Reimbursement of research and development expense	194	0
Research and development expense, net of reimbursements	$4,218	$1,320

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Total property and equipment	$22,282	$22,120
Less accumulated depreciation	17,608	17,285
Property and equipment, net	4,674	4,835
Equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	8,698	8,552
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	375	375
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	$13,209	$13,193

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$323	$308

Debt_Obligations_Additional_In

Debt Obligations - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	7-May-14	Jun. 30, 2014	Dec. 31, 2014	Apr. 30, 2010	Dec. 31, 2011	Jun. 30, 2013
Debt Instrument [Line Items]
Amortization of deferred financing costs	$0	$536
Number of warrants issued to purchase common stock	14,033				14,033
2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount						15,000
Interest at a rate of London InterBank plus						0.95%
2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Deemed contribution of a loan guarantee		3,930
Outstanding debt plus accrued interest			15,000
Gains (Losses) on Extinguishment of Debt				1,389
Debt Outstanding	0				0
Amortization of deferred financing costs	0	536
December 2011 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity							15,000
2011-2012 Notes [Member]
Debt Instrument [Line Items]
Convertible notes aggregate amount	0				0
Exercise price of warrants							$0.20
Interest Payable	0				0
June 2013 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity								1,500
Convertible notes aggregate amount	0				0			899
Interest Payable	0				0
Investor [Member] | 2011-2012 Notes [Member]
Debt Instrument [Line Items]
Convertible notes aggregate amount							11,444
Number of warrants issued to purchase common stock							26,000
Term Loan [Member] | 2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount						5,000
Revolving Credit Facility [Member] | 2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount						$10,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2015	Mar. 31, 2014
		Agreement
Commitment And Contingencies [Line Items]
Lease expiration		2019
Lease expiration extension		31-Mar-24
Rent expense		$218	$231
Milestone payments from the Company		19,000
Number of additional license agreements		2
License agreements fee		2,300
Services agreement, days required between notice and termination of agreement	30 days
Research and Development Arrangement [Member]
Commitment And Contingencies [Line Items]
Success fee payable		$500
Percentage Of transaction consideration		4.00%

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
2015	$826
2016	1,122
2017	1,140
2018	1,161
2019	291
Thereafter	0
Total	$4,540

Convertible_Preferred_Stock_Ad

Convertible Preferred Stock - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		1 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 13, 2014	Mar. 31, 2015	Mar. 31, 2014	Jul. 31, 2006	Jan. 31, 2014	Dec. 11, 2013	Dec. 31, 2014	31-May-14	7-May-14
Temporary Equity [Line Items]
Ipo Gross Proceeds Threshold That Triggers Automatic Conversion Of Preferred Stock	$20,000
Convertible Preferred Stock, Shares Issued upon Conversion									1,691,884
Outstanding Series C-1 Preferred warrants		14,033					14,033
Class of Warrant or Right, Exercise Price of Warrants or Rights								$0.20
Other (expense) income related to fair value adjustment of long term derivative liability			-3,145
Proceeds from Issuance of Preferred Stock and Preference Stock		0	544
Excess of fair value of warrants over proceeds			362
Series C-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding Series C-1 Preferred warrants				196,923
Class of Warrant or Right, Exercise Price of Warrants or Rights				$3.25
Class Of Warrant Expiration Date		14-Jul-16
Fair Value Of Warrant On Issuance Date				459
Other (expense) income related to fair value adjustment of long term derivative liability		0	37
Common Stock [Member]
Temporary Equity [Line Items]
Outstanding Series C-1 Preferred warrants				14,033
Class of Warrant or Right, Exercise Price of Warrants or Rights				$45.61
Series D-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding Series C-1 Preferred warrants					19,048	87,532
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.20	$0.20
Fair Value Of Warrant On Issuance Date					906	4,214
Temporary Equity, Shares Issued					388,641	1,785,712
Temporary Equity Shares Issue Price					$1.40	$1.40
Proceeds from Issuance of Preferred Stock and Preference Stock					544	2,500
Payments of Stock Issuance Costs						95
Excess of fair value of warrants over proceeds					$362	$1,714

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	0 Months Ended			3 Months Ended	0 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	31-May-14	7-May-14	2-May-14	Mar. 31, 2014	Dec. 11, 2013	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Capitalization, Equity [Line Items]
Common stock, par value						$0.00	$0.00
Common stock, shares authorized						125,000,000	125,000,000
Common stock, shares issued						8,527,210	8,512,103
Common stock, shares outstanding						8,527,210	8,512,103
Number of warrants issued to purchase common stock						14,033	14,033
Exercise price of warrants	$0.20
Exercise of common stock warrants	275,687	275,687
Fair value of common stock warrant derivative liabilities				$9,998				$12,200
Warrant derivative liability reclassified to additional paid-in capital			2,701
Other (expense) income related to fair value adjustment of long term derivative liability				-3,145
Series D-2 Purchase Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock					87,532
Exercise price of warrants					$0.20
Warrants exercisable date					11-Dec-18
Increase in the shares of common stock underlying the warrants issued					54,120
Revised number of common shares underlying the warrants issued					80,120
Common Stock Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Other (expense) income related to fair value adjustment of long term derivative liability				$3,108		$0
2011-2012 Notes [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock									26,000
Exercise price of warrants									$0.20
June 2013 Note and Warrant Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock					88,987
Exercise price of warrants					$0.20
Warrants exercisable date					28-Jun-18

Common_Stock_Summary_of_Common

Common Stock - Summary of Common Stock Shares Activity (Detail)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Beginning Balance	8,512,103
Common stock issued through employee stock purchase plan	15,107
Ending Balance	8,527,210

Common_Stock_Schedule_of_Reser

Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail)	Mar. 31, 2015	Mar. 26, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Outstanding stock options	575,416		615,322
Outstanding Series C-1 Preferred warrants	14,033		14,033
Total common shares reserved for future issuance	1,652,499		847,711
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
For possible future issuance under 2014 Equity Incentive Plan (Note 8)	561,000		180,610
2014 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
For possible future issuance under 2014 Equity Incentive Plan (Note 8)	52,050		37,746
2015 Inducement Plan [Member]
Class of Stock [Line Items]
For possible future issuance under 2014 Equity Incentive Plan (Note 8)	450,000	450,000	0

Stockbased_Compensation_2009_S

Stock-based Compensation 2009 Stock Option Plan (Details) (2009 Stock Option Plan [Member])	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	100.00%
Vesting period of options	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	110.00%
Vesting period of options	4 years

Stockbased_Compensation_2014_E

Stock-based Compensation 2014 Equity Incentive Plan (Details)	0 Months Ended			3 Months Ended
	Feb. 25, 2015	Jan. 01, 2015	Jun. 18, 2014	Mar. 31, 2015	Dec. 31, 2014	2-May-14
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effective date of equity incentive plan				2-May-14
Common stock outstanding percentage				4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period				0
Aggregate number of shares of the Company's common stock that may be issued	510,726	340,484	351,653
Possible future issuance under equity compensation plan				561,000	180,610
2009 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional awards expected to be granted						0
Maximum [Member] | 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base number of new shares available for future issuance under equity incentive plan				257,352
Common stock issuable period				10 years
Chief Medical Officer [Member] | 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares		57,452

Stockbased_Compensation_2015_I

Stock-based Compensation - 2015 Inducement Plan (Details) (2015 Inducement Plan [Member])	Mar. 31, 2015	Mar. 26, 2015	Dec. 31, 2014
2015 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Possible future issuance under equity compensation plan	450,000	450,000	0

Stockbased_Compensation_2014_E1

Stock-based Compensation 2014 Employee Stock Purchase Plan (Details)	0 Months Ended			3 Months Ended
	Feb. 25, 2015	Jan. 01, 2015	Jun. 18, 2014	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued through employee stock purchase plan				15,107
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding percentage				4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period				0
Aggregate number of shares of the Company's common stock that may be issued	510,726	340,484	351,653
Possible future issuance under equity compensation plan				561,000	180,610
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effective date of employee stock purchase plan				2-May-14
Common stock issuable period				10 years
Common stock outstanding percentage				0.80%
Employee stock purchase plan, number of shares, which might be added to common stock outstanding				29,411
Number of shares of common stock for future issuance, board of directors prerogative, increase in period				0
Aggregate number of shares of the Company's common stock that may be issued				29,411
Possible future issuance under equity compensation plan				52,050	37,746
2014 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
For possible future issuance under employee stock purchase plan				47,794

Stockbased_Compensation_Compen

Stock-based Compensation Compensation Cost (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation cost	$296	$110
Cash received from option exercised	0	5
Tax benefit from compensation expense	$0	$0

Stockbased_Compensation_Stockb

Stock-based Compensation - Stock-based Compensation Expense Related to Stock Options (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$296	$110
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	33	13
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	52	62
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$211	$35

Net_Loss_Summary_of_Computatio

Net Loss - Summary of Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net (loss) income	($6,384)	$412
Deemed dividend for beneficial conversion feature on Series D-2 Preferred	0	-909
Deemed dividend for antidilution adjustments to convertible preferred stock	0	-214
Accretion of convertible preferred stock	0	-510
Net loss attributable to common stockholders - basic	-6,384	-1,221
Derivative fair value adjustment	0	-2,783
Net loss attributable to common stock - diluted	($6,384)	($4,004)
Weighted-average common shares outstanding - basic	8,516,467	334,086
Incremental shares from assumed exercise of common stock warrants	0	274,988
Weighted-average of outstanding common stock - diluted	8,516,467	609,074
Basic	($0.75)	($3.65)
Diluted	($0.75)	($6.57)

Net_Loss_Per_Share_Summary_of_

Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	6,149
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	131,685
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	783,515
Series C-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	173,213
Series D-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	296,773
Series D-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	300,549
Warrant [Member] | Series C-1 Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	14,033	14,033
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	575,416	184,240
Employee Stock Purchase Plan[Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	40,334	0

RelatedParty_Transaction_Summa

Related-Party Transaction - Summary of Transactions with Related Parties (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Related Party Transactions [Abstract]
Revenue	$987	$1,822

RelatedParty_Transactions_Addi

Related-Party Transactions - Additional Information (Detail) (Sanofi [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Related Party Transaction [Line Items]
Ownership percentage of a related party in a customer of the company	100.00%
Sales [Member]
Related Party Transaction [Line Items]
Percentage of related-party revenue	30.00%	39.00%

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net [Abstract]
Beginning balance	$12,237
Issuance of warrants	544
Excess of fair value of warrants over proceeds	362
Adjustment to fair value	-3,145
Ending balance	$9,998

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Details) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	2-May-14
Fair Value Disclosures [Abstract]
Warrant derivative liability reclassified to additional paid-in capital	$2,701

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended
In Thousands, except Share data, unless otherwise specified	7-May-14	Apr. 28, 2015	Apr. 01, 2015	1-May-15	12-May-15
Subsequent Event [Line Items]
Number of shares of common stock sold	6,200,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Options granted			425,967
Number of shares of common stock sold		5,376,622
Public offering price per share		$7.70
Proceeds from issuance of common shares		$37,754
Underwriting discounts and commissions		3,646
Compensatory Plan with Service Business Employees [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Expiration period of options				48 months
Maximum incentive compensation				1,300
Outstanding options (in shares)				55,964
Outstanding options, weighted average exercise price (in USD per share)				$9.62
Unvested options (in shares)				33,274
Unvested options, weighted average exercise price (in USD per share)				$9.62
Compensatory Arrangement with Executive Officer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Outstanding options, weighted average exercise price (in USD per share)					$9.53
Unvested options (in shares)					50,814
Unvested options, weighted average exercise price (in USD per share)					$9.49
Employee Stock Option [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Expiration period of options			10 years
Tranche one | Subsequent Event [Member]
Subsequent Event [Line Items]
Vesting percentage				25.00%
Vesting period, tranche one				1 year
Remaining tranches | Subsequent Event [Member]
Subsequent Event [Line Items]
Vesting period, remaining tranches				36 years
Chief Executive Officer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Options granted			330,000
Executive Officer [Member] | Compensatory Arrangement with Executive Officer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash payment due					138
Severance Costs					$179
Number of options held by employee in end of quarter					74,490